Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Predictive Value of the Albumin-Bilirubin Score and the C-Reactive Protein-Albumin-Lymphocyte Index for the Prognosis of Patients With Hepatocellular Carcinoma After Radical Resection

NCT06934070 is registered in ClinicalTrials.gov with Qiang Xu as lead sponsor.

NCT NCT06934070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06934070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Predictive Value of the Albumin-Bilirubin Score and the C-Reactive Protein-Albumin-Lymphocyte Index for the Prognosis of Patients With Hepatocellular Carcinoma After Radical Resection
Lead sponsor
Qiang Xu
Phase
Observational
Overall status
Active, not recruiting
Start date
April 3, 2025
Completion date
April 16, 2025
Enrollment
287 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc), hepatocellular carcinoma (hcc) prognosis